Anthropic said Claude, scanning public DNA catalogs, linked a known RNA-to-DNA copying enzyme with a stretch of repeating DNA and a nearby mystery protein in giant viruses that infect bacteria.
The function of the enzyme system is still unproven.
CRISPR pioneer Feng Zhang of MIT and the Broad Institute called the RNA-repeat finding “genuinely intriguing” and said it “merits further investigation.”
Gene-editing stocks sold off on Wednesday after Anthropic said its Claude model had flagged a phage enzyme system that shares a few design traits with CRISPR — the platform behind approved and experimental DNA-editing medicines.
Shares of CRISPR Therapeutics (CRSP) slipped about 6% from Tuesday’s $59.03 close. Intellia (NTLA) and Beam (BEAM) dropped 3% and 6%, respectively. Prime Medicine (PRME) fell about 12% after a double-digit Tuesday bounce, while shares of Editas Medicine (EDIT) closed down 8% after opening 7% higher.
The market read was about optionality, not a rival drug. Anthropic said Claude, scanning public DNA catalogs, linked a known RNA-to-DNA copying enzyme with a stretch of repeating DNA and a nearby mystery protein in giant viruses that infect bacteria. It named the three-part package ART.
The repeats look a bit like CRISPR’s targeting “memory bank” and are copied into short RNAs, the company said. That mix of features, Anthropic added, has shown up together in only a handful of programmable systems that can cut, copy, or paste DNA. The enzyme itself was already in the literature; the claimed first is the full combo sitting together. Function is still unproven.
CRISPR pioneer Feng Zhang of MIT and the Broad Institute called the RNA-repeat finding “genuinely intriguing” and said it “merits further investigation.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.